• Stiripentol as an LDH Inhibitor in Metabolic Research

  2026-08-13

  Stiripentol gives researchers a practical way to perturb LDH-dependent lactate and pyruvate flux while connecting seizure biology with emerging lactate-driven epigenetic assays. This workflow emphasizes formulation control, paired metabolic readouts, and careful separation of established epilepsy evidence from hypothesis-generating tumor immunometabolism applications.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-13

  This study develops patient-derived gastric cancer assembloids by combining matched tumor organoids with stromal subpopulations from the same tumor tissue. The model captures microenvironment-dependent changes in gene expression and drug response, creating a more physiologically relevant platform for tumor–stroma research and personalized treatment testing.

• CCR7–Notch1 Crosstalk Drives Mammary Tumor Stemness

  2026-08-12

  Boyle and colleagues identify a functional signaling connection between CCR7 and Notch1 in primary MMTV-PyMT mammary cancer cells. Their perturbation-based experiments show that CCR7 stimulation activates Notch1 and that Notch inhibition suppresses CCR7-dependent stem-like behavior, providing a mechanistic rationale for studying both axes together.

• ATRX Loss and RTK/PDGFR Sensitivity in Glioma

  2026-08-12

  The reference study shows that ATRX-deficient high-grade glioma cells are preferentially vulnerable to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors. Its genotype-aware drug-screening strategy also identifies a stronger response when selected RTK inhibitors are combined with temozolomide, supporting ATRX status as a useful variable for preclinical design and clinical-trial interpretation.

• N2-Alkyl-dG Lesions and R-Loop Accumulation

  2026-08-11

  The 2024 Nucleic Acids Research study identifies minor-groove N2-alkyl-dG lesions as a previously unrecognized trigger of R-loop accumulation in chromatin and plasmid DNA. By combining fluorescence microscopy, R-loop sequencing, genetic perturbation, and functional assays, the authors connect these lesions with transcription elongation defects, genome instability, and increased sensitivity to a carcinogenic alkylating agent.

• Bacitracin B1670: Practical Research Guide

  2026-08-11

  Bacitracin B1670 is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis disruption. This guide covers dissolution, storage, assay controls, and troubleshooting; the material is for scientific research only and should not be used for diagnostic, clinical, or medical purposes.

• Mestranol and Reversible Lysosomal Stress in Microglia

  2026-08-10

  A 2026 zebrafish study identifies mestranol as an inducer of a reversible lysosomal storage–like state in microglia. The work separates phagocytic uptake from intracellular digestion and provides a live model for investigating environmental estrogen-associated neuroimmunotoxicity.

• DNase I for Translational RNA Workflow Control

  2026-08-09

  Mechanistic oncology is only as reliable as the nucleic-acid workflows used to validate it. This thought-leadership guide connects CAF-derived lactate, ANTXR1 lactylation, and oxaliplatin resistance with disciplined DNA removal, chromatin handling, and translational assay design using DNase I (RNase-free).

• Chlorpromazine HCl for Endocytosis Assays

  2026-08-08

  Chlorpromazine HCl gives researchers a practical way to perturb clathrin-dependent uptake while preserving a well-established dopamine receptor antagonist profile. This guide translates infection-biology evidence into controlled cell assays, neuronal workflows, comparative controls, and troubleshooting decisions.

• Stable Yeast Expression of Exendin-4 for T2D

  2026-08-07

  Balius et al. developed recombinant Exendin-4 expression models in Escherichia coli and Saccharomyces cerevisiae, with chromosomal integration in yeast producing immunoreactive protein at the expected size. The work establishes a proof of concept for a potentially more accessible production platform while emphasizing that purification, bioactivity, dosing, and therapeutic safety remain to be demonstrated.

• Ibrexafungerp (MK 3118): Translational Antifungal Strategy R

  2026-08-07

  Explore how Ibrexafungerp (MK 3118) is transforming translational antifungal research by uniting molecular insight, robust protocol guidance, and practical clinical considerations. This article synthesizes recent evidence, including pivotal in vitro and in vivo findings, to provide actionable strategies for researchers confronting resistant Candida infections and optimizing therapy for vulvovaginal candidiasis.

• 2-NBDG Glucose Uptake Assay Kit: Precision in Cell Metabolis

  2026-08-06

  The 2-NBDG Glucose Uptake Assay Kit enables rapid, non-radioactive quantification of glucose uptake at the single-cell level. Its use of a fluorescent glucose analogue and built-in GLUT1 inhibition control make it a superior tool for studies in cancer and metabolic disease. This article details its mechanism, benchmarks, and correct use for robust glucose metabolism research.

• IWP-2: Wnt Production Inhibitor Transforming Cancer Research

  2026-08-06

  IWP-2, a potent Wnt production inhibitor from APExBIO, empowers researchers with precise modulation of the Wnt/β-catenin pathway. Its versatility in cell-based, apoptosis, and regenerative workflows addresses key bottlenecks in cancer and stem cell studies, enabling reproducible results and advanced experimental designs.

• 2,5-di-tert-butylbenzene-1,4-diol (BHQ): Next-Gen Tools for

  2026-08-05

  Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) transforms calcium signaling research and stem cell mobilization through selective SERCA inhibition. This article dives deeper into mechanistic insights, practical assay implications, and the future of HSC mobilization strategies.

• PP2A-Mediated Autophagy Drives Drug Resistance in C. albican

  2026-08-05

  This study establishes that protein phosphatase 2A (PP2A) modulates biofilm drug resistance in Candida albicans by orchestrating autophagy through ATG protein phosphorylation. These findings clarify the mechanistic link between autophagy induction and antifungal therapy failure, revealing PP2A as a promising target for future strategies against resilient C. albicans infections.

11587 records 1/773 page Next 12345 下5页 Last page